CareDx Inc. stocks have been trading up by 19.13 percent after upbeat transplant diagnostics coverage sparked renewed investor optimism.
Key Takeaways
- Q3 revenue near $139M–$139.4M smashed the roughly $122M consensus, powered by Transplant strength, scaling Specialty Oncology, and pipeline progress.
- Profitability jumped, with GAAP EPS at $0.35 and adjusted EPS at $0.70, a sharp lift from last year’s $0.03.
- Full-year 2026 revenue guidance was raised to $520M–$530M and adjusted EBITDA to $90M–$100M, both well above prior targets and Street expectations.
- Canaccord and BTIG lifted price targets to $80 and $81 while keeping Buy ratings, flagging strong fundamentals and room for further growth in CDNA.
- Fresh AlloSure Kidney and AlloSure Plus data from ASN Kidney Week 2026 reinforced clinical strength, showing fewer biopsies and strong rejection prediction under updated Banff 2024 criteria.
Live Update At 15:03:31 EDT: On Friday, October 30, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 19.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CDNA has shifted from a quiet grinder to a clear momentum name. Over the last few weeks, CareDx climbed from around $64 on 2026/10/16 to $85.20 on 2026/10/30. That is a strong trend, not a random pop. The big acceleration hit right after earnings, with CDNA jumping from a 10/29 close of $71.52 to a high near $90.87 on 10/30 before settling in the mid‑$80s.
Intraday action on the latest session shows classic momentum behavior. CDNA opened around $80.61, ripped quickly into the high $80s and tagged $90.87, then consolidated mostly between $84 and $88. For short-term traders, that’s a wide intraday range with plenty of liquidity and clean scalping opportunities.
More Breaking News
- SNDG ETF Slides As Volatility Grips Short-Term Traders
- NCPL Stock Holds Key Levels As Traders Study Volatile Chart
- BOOT Stock Jumps As Earnings Beat Fuels Buy Ratings
- NRXP Stock Builds Momentum As FDA Ketamine Catalyst Nears
Under the hood, CareDx is not just a story stock. Key ratios show a gross margin above 70% and healthy cash flow metrics, backed by low leverage and a current ratio above 4. CDNA’s recent quarter delivered operating revenue of about $139.4M and net income near $19.3M, showing the business is scaling. For traders, that combination of earnings power, guidance strength, and technical momentum makes CDNA a name to keep on the screen, while always respecting risk and volatility.
Why Traders Are Watching CDNA Right Now
CDNA is on the radar because the company finally lined up all three pillars momentum traders care about: a big earnings beat, bullish guidance, and analyst upgrades. CareDx reported Q3 revenue around $139M–$139.4M against expectations near $122M. That is a serious beat in the diagnostics space. CDNA’s Q3 GAAP EPS jumped to $0.35 from $0.03 a year ago, and adjusted EPS printed at $0.70, signaling that CareDx is not just growing sales; it’s converting growth into real profits.
Management then doubled down with aggressive 2026 outlooks. CareDx lifted its revenue guidance to $520M–$530M, well ahead of the roughly $495M Street view and prior $490M–$500M range. It also boosted 2026 adjusted EBITDA guidance to $90M–$100M from $66M–$78M. When a company pushes revenue and earnings expectations higher at the same time, traders pay attention. It often forces analysts to chase estimates upward and can support a higher valuation for CDNA.
The Street’s reaction backed that view. Canaccord raised its price target on CareDx to $80 from $65, calling the stock undervalued with strong fundamentals. BTIG took its target from $74 to $81 while keeping a Buy rating, leaning on solid growth in life science and diagnostic tools. Those target hikes give momentum traders a visible “story” to trade around.
On top of numbers, CareDx delivered new data at ASN Kidney Week 2026. Multiple independent studies showed AlloSure Kidney and AlloSure Plus reduce the need for invasive biopsies and still strongly predict rejection risk, even with updated Banff 2024 criteria. That clinical validation supports the long-term demand story behind CDNA’s transplant testing franchise, reinforcing why the market is willing to reward the stock after strong Q3 results.
Conclusion
For active traders, CDNA now looks like a textbook example of how strong fundamentals can light a fire under a chart. CareDx delivered big Q3 revenue upside, with about $139M–$139.4M versus roughly $122M expected, and drove GAAP EPS to $0.35 and adjusted EPS to $0.70. Then it raised 2026 revenue guidance to $520M–$530M and boosted adjusted EBITDA goals to $90M–$100M. That one-two punch shifted the narrative from “promising” to “executing.”
Analysts responded, with Canaccord and BTIG lifting price targets to $80 and $81 and reaffirming their bullish stances on CDNA. Meanwhile, new AlloSure Kidney data from ASN Kidney Week 2026 underlined CareDx’s edge in transplant testing, reducing biopsies while maintaining strong prediction power under the newer Banff 2024 framework. That kind of science-backed moat matters when traders assess whether the revenue ramp is sustainable.
From a trading perspective, CDNA’s recent spike from the $60s into the mid‑$80s demands respect. There is clear momentum, but also real volatility. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful gamblers.” The same mindset is echoed in the pre‑market routine championed by many educators; as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” For anyone tracking CDNA, that means studying the earnings, guidance, clinical story, and the chart — and always having a plan to cut losses fast if the trend breaks. This analysis is for educational and research purposes only, not advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.